Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma

Allison R. Valerius; Lauren M. Webb; Anna Thomsen; Eric J. Lehrer; William G. Breen; Jian L. Campian; Cecile Riviere-Cazaux; Terry C. Burns; Ugur Sener

doi:10.3390/ijms251910570

Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma

Allison R. Valerius, Lauren M. Webb, Anna Thomsen, Eric J. Lehrer, William G. Breen, Jian L. Campian, Cecile Riviere-Cazaux, Terry C. Burns, Ugur Sener

Research output: Contribution to journal › Review article › peer-review

Abstract

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite an established standard of care including surgical resection, radiation therapy, and chemotherapy, GBM unfortunately is associated with a dismal prognosis. Therefore, researchers are extensively evaluating avenues to expand GBM therapy and improve outcomes in patients with GBM. In this review, we provide a broad overview of novel GBM therapies that have recently completed or are actively undergoing study in clinical trials. These therapies expand across medical, surgical, and radiation clinical trials. We additionally review methods for improving clinical trial design in GBM.

Original language	English
Article number	10570
Journal	International Journal of Molecular Sciences
Volume	25
Issue number	19
DOIs	https://doi.org/10.3390/ijms251910570
State	Published - Oct 2024
Externally published	Yes

Keywords

glioblastoma
high-grade glioma
immunotherapy
radiation therapy
review of therapy
surgical therapy
targeted molecular therapy

Access to Document

10.3390/ijms251910570

Cite this

@article{bb01c0fed7ca4cfc81d18aa6167476d7,

title = "Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma",

abstract = "Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite an established standard of care including surgical resection, radiation therapy, and chemotherapy, GBM unfortunately is associated with a dismal prognosis. Therefore, researchers are extensively evaluating avenues to expand GBM therapy and improve outcomes in patients with GBM. In this review, we provide a broad overview of novel GBM therapies that have recently completed or are actively undergoing study in clinical trials. These therapies expand across medical, surgical, and radiation clinical trials. We additionally review methods for improving clinical trial design in GBM.",

keywords = "glioblastoma, high-grade glioma, immunotherapy, radiation therapy, review of therapy, surgical therapy, targeted molecular therapy",

author = "Valerius, {Allison R.} and Webb, {Lauren M.} and Anna Thomsen and Lehrer, {Eric J.} and Breen, {William G.} and Campian, {Jian L.} and Cecile Riviere-Cazaux and Burns, {Terry C.} and Ugur Sener",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = oct,

doi = "10.3390/ijms251910570",

language = "English",

volume = "25",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "19",

}

TY - JOUR

T1 - Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma

AU - Valerius, Allison R.

AU - Webb, Lauren M.

AU - Thomsen, Anna

AU - Lehrer, Eric J.

AU - Breen, William G.

AU - Campian, Jian L.

AU - Riviere-Cazaux, Cecile

AU - Burns, Terry C.

AU - Sener, Ugur

PY - 2024/10

Y1 - 2024/10

N2 - Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite an established standard of care including surgical resection, radiation therapy, and chemotherapy, GBM unfortunately is associated with a dismal prognosis. Therefore, researchers are extensively evaluating avenues to expand GBM therapy and improve outcomes in patients with GBM. In this review, we provide a broad overview of novel GBM therapies that have recently completed or are actively undergoing study in clinical trials. These therapies expand across medical, surgical, and radiation clinical trials. We additionally review methods for improving clinical trial design in GBM.

AB - Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite an established standard of care including surgical resection, radiation therapy, and chemotherapy, GBM unfortunately is associated with a dismal prognosis. Therefore, researchers are extensively evaluating avenues to expand GBM therapy and improve outcomes in patients with GBM. In this review, we provide a broad overview of novel GBM therapies that have recently completed or are actively undergoing study in clinical trials. These therapies expand across medical, surgical, and radiation clinical trials. We additionally review methods for improving clinical trial design in GBM.

KW - glioblastoma

KW - high-grade glioma

KW - immunotherapy

KW - radiation therapy

KW - review of therapy

KW - surgical therapy

KW - targeted molecular therapy

UR - http://www.scopus.com/inward/record.url?scp=85206451214&partnerID=8YFLogxK

U2 - 10.3390/ijms251910570

DO - 10.3390/ijms251910570

M3 - Review article

AN - SCOPUS:85206451214

SN - 1661-6596

VL - 25

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 19

M1 - 10570

ER -

Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this